Michael Wang, MD

Anthony R. Mato, MD, MSCE, introduces the panel, and Alexey V. Danilov, MD, PhD, provides an overview of the incidence, presentation, pathologic features, and treatment landscape for mantle cell lymphoma.

Michael Wang, MD, discusses the results of the phase 3 SHINE trial in older patients with mantle cell lymphoma.

Michael Wang, MD, discusses adverse effects associated with BTK inhibitors in patients with mantle cell lymphoma.

Closing out their discussion on B-cell malignancies, expert panelists share clinical pearls on the management of marginal zone lymphoma.

A comprehensive review of novel therapies in relapsed/refractory marginal zone lymphoma and possible sequencing strategies in this setting.

Michael Wang, MD, discusses potential adverse effects associated with ibrutinib in patients with mantle cell lymphoma.

Michael Wang, MD, discusses the sequencing of oral therapies in mantle cell lymphoma.

Shared insight on frontline treatment approaches for patients diagnosed with marginal zone lymphoma.

Clinical pearls for community physicians regarding the optimal management of patients with follicular lymphoma.

Michael Wang, MD, discusses the evolution of ibrutinib in the treatment landscape of mantle cell lymphoma.

Panelists use an illustrative clinical case to comprehensively discuss the selection and sequencing of therapies for patients with follicular lymphoma.

A review of the role of PI3K inhibitors in the treatment of follicular lymphoma, and how they have been used to improve patient outcomes.

Michael Wang, MD, discusses the evolving treatment landscape of mantle cell lymphoma.

Expert perspectives on novel approaches to treatment in the relapsed/refractory setting, particularly CAR T-cell therapy, for patients with follicular lymphoma.

Shared insight on the indolent nature of follicular lymphoma and frontline therapy options for this disease.

Closing out their discussion on mantle cell lymphoma, expert panelists share clinical pearls for practicing community physicians.

Panelists use an illustrative clinical case to highlight best practices in sequencing therapy for mantle cell lymphoma and discuss novel combination strategies under investigation.

A brief review of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma as studied in the ZUMA-2 clinical trial of brexucabtagene autoleucel.

Moving to second-line therapy for mantle cell lymphoma, experts discuss available BTK inhibitors, including the novel agent pirtobrutinib.

Shared insight on the optimal selection and use of frontline therapy for patients who present with mantle cell lymphoma.

Expert panelists discuss a number of recent updates in B-cell lymphoma, particularly mantle cell lymphoma, follicular lymphoma and marginal zone lymphoma, that were presented at key conferences in 2021.

Michael Wang, MD, discusses the significance of p53 mutations in mantle cell lymphoma.

Michael Wang, MD, discusses the use of acalabrutinib in the phase 2 ACE-LY-004 trial in mantle cell lymphoma.

Michael Wang, MD, discusses the importance of additional CAR T-cell therapy research in mantle cell lymphoma.

Michael Wang, MD, discusses the safety profile of ​the CAR T-cell therapy brexucabtagene autoleucel in ​relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the FDA approval of brexucabtagene autoleucel (Tecartus; formerly KTE-X19) in mantle cell lymphoma (MCL).

Michael Wang, MD, discusses the efficacy of KTE-X19 in low- and high-risk patients with relapsed/refractory mantle cell lymphoma as part of the phase 2 ZUMA-2 trial.

Michael Wang, MD, discusses the objectives of a comparative analysis of the phase 2 ZUMA-2 trial with KTE-X19 in patients with mantle cell lymphoma.

Michael Wang, MD, discusses the safety and efficacy of KTE-X19 in relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, discusses the safety and effectiveness of the autologous anti-CD19 CAR T-cell therapy KTE-X19 in patients with higher- versus lower-risk mantle cell lymphoma.